A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects with Cystic Fibrosis Who are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) VX17-659-102